Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoroglutamine
- Development stage
- Unknown
- Lead developer
- Renaissance School of Medicine at Stony Brook University
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fluoroglutamine, specifically in its radiolabeled form [18F]fluoroglutamine (FG), is a positron emission tomography (PET) radiotracer used to image glutamine metabolism in vivo. Cancer cells often exhibit glutamine dependence, upregulating transporters and metabolic pathways to support rapid proliferation. [18F]fluoroglutamine acts as a metabolic probe that is internalized by cells primarily via the SLC1A5 (ASCT2) transporter. Its uptake reflects the activity of the serine synthesis pathway (SSP), which is frequently upregulated in TP53-mutant and HER2-positive breast cancers. The tracer is being developed to identify tumors with high SSP activity and to guide the selection of patients for SSP-targeted or glutamine-targeted therapies.
- Other names
- 4-fluoroglutamine(2S,4R)-4-fluoroglutamine[18F](2S,4R)4-fluoroglutamine[18F]fluoroglutamine
02
Targets
SLC1A5 (Alanine/serine/cysteine transporter 2)
Beyond the preview
Go deeper on fluoroglutamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoroglutamine.